The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity-Reference-Cited by-同舟云学术

The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

Published:2014-11-17 Issue:11 Volume:9 Page:e112394
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Oelze Matthias,Kröller-Schön Swenja,Welschof Philipp,Jansen Thomas,Hausding Michael,Mikhed Yuliya,Stamm Paul,Mader Michael,Zinßius Elena,Agdauletova Saule,Gottschlich Anna,Steven Sebastian,Schulz Eberhard,Bottari Serge P.,Mayoux Eric,Münzel Thomas,Daiber Andreas

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference50 articles.

1. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes;DM Nathan;N Engl J Med,2005

2. Oxidative stress and diabetic cardiovascular complications;D Jay;Free Radic Biol Med,2006

3. Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus;U Hink;Circ Res,2001

4. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus;P Wenzel;Atherosclerosis,2008

5. AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats;P Wenzel;Free Radic Biol Med,2008

Cited by 241 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Cardiovascular Outcomes: A Review of Literature;Cureus;2024-07-04

2. Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies;International Journal of Molecular Sciences;2024-07-02

3. The current landscape for diabetes treatment: Preventing diabetes-associated CV risk;Atherosclerosis;2024-07

4. Neuroprotective Effects of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors (Gliflozins) on Diabetes-Induced Neurodegeneration and Neurotoxicity: A Graphical Review;International Journal of Preventive Medicine;2024-06

5. Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project);JMIR Research Protocols;2024-05-29